权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Modeling the HIV latent reservoir, latency reversal and immunotherapeutics for HIV cure

为 HIV 治愈建立 HIV 潜伏库、潜伏期逆转和免疫疗法的模型

基本信息

批准号：
10083086
负责人：
Ruian Ke
金额：
$ 60.35万
依托单位：
TRIAD NATIONAL SECURITY, LLC
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-01 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10083086
关键词：
Address Affinity Aftercare Agonist Antibodies Biological Biological Markers Bispecific Antibodies CD8-Positive T-Lymphocytes CD8B1 gene Cells Characteristics Clinical Clinical Data Clinical Trials Combined Modality Therapy Complex Coupled Data Data Set Detection Development Disease remission Effectiveness Effector Cell Exhibits Favorable Clinical Outcome Foundations Future Grant HIV HIV-1 Immune Immune response Immune system Immunologic Markers Immunotherapeutic agent In Vitro Individual Integration Host Factors Interruption Intervention Knowledge Lead Light Macaca Macaca mulatta Measurement Measures Medical Modeling Outcome Patients Public Health Research Response Latencies Role System TLR7 gene Testing Therapeutic Therapeutic Intervention Treatment Efficacy Treatment outcome Viral Viral Load result Withholding Treatment Work acute infection antiretroviral therapy base design effective intervention effective therapy experimental study in vivo latent HIV reservoir mathematical model neutralizing antibody next generation outcome prediction pandemic disease patient population response therapeutic development tool treatment strategy viral rebound

项目摘要

SUMMARY A major barrier to HIV cure is the reservoir of latently infected cells that persists in patients treated with highly potent antiretroviral treatment (ART). Activation of these latently infected cells can lead to HIV rebound in the absence of ART. In clinical trials, HIV exhibits widely different dynamics after ART cessation. HIV rebounds rapidly in most individuals, whereas in a small fraction of individuals, prolonged HIV remission or post-treatment control (PTC) is achieved. Despite intensive research, we lack a clear and coherent understanding of the determinants of viral control or the duration of HIV remission after ART, which hinders the development of effective therapeutic strategies to achieve a ‘functional’ cure and ultimately a sterilizing cure. This grant addresses this gap in knowledge. Our central hypothesis is that PTC is not solely driven by a single factor; rather, it is a phenomenon emerging from complex nonlinear interactions between the immune response and the latent reservoir, including both the replication competent reservoir and the defective reservoir. Understanding this dynamical interaction will be key to develop effective interventions to achieve favorable clinical outcomes. We will first delineate the roles of these interactions in determining viral control through integration of recent biological findings into a mechanistic mathematical model. We will validate this model using clinical data from post-treatment controllers and non-controllers, correlate estimated model parameters with measured biological and immunological markers to identify patient characteristics that predict PTC. Further, we will estimate the mode of action and quantify the efficacy of a next-generation latency reversing agent (LRA), AZD5582, and a class of promising bispecific antibody-based immunotherapeutics, the Dual-Affinity Re-Targeting molecules. Finally, we will integrate models of how these agents work with a model of the interaction of the latent reservoir with the immune system to evaluate and predict the impact of combinations of LRAs and immunotherapeutics on the reservoir and on clinical outcomes. Altogether, our work will provide a theoretical foundation for 1) understanding HIV control and rebound dynamics after ART, 2) identifying patients who are likely to achieve PTC, 3) estimating/predicting the impact of therapeutic interventions such as LRAs and/or immunotherapeutics, and 4) suggesting effective interventions to achieve a ‘functional’ cure according to patient characteristics.

总结